Opiant Pharmaceuticals Inc (NASDAQ:OPNT) – Zacks Investment Research lifted their Q2 2018 earnings per share (EPS) estimates for shares of Opiant Pharmaceuticals in a report issued on Wednesday, according to Zacks Investment Research. Zacks Investment Research analyst D. Bautz now expects that the technology company will post earnings per share of $3.76 for the quarter, up from their previous estimate of ($1.24). Zacks Investment Research also issued estimates for Opiant Pharmaceuticals’ Q3 2018 earnings at ($0.36) EPS, Q4 2018 earnings at ($0.50) EPS, FY2018 earnings at $0.17 EPS, FY2019 earnings at ($1.00) EPS and FY2020 earnings at $3.43 EPS.
A number of other brokerages have also issued reports on OPNT. TheStreet upgraded Opiant Pharmaceuticals from a “c+” rating to a “b” rating in a report on Monday, October 16th. ValuEngine downgraded shares of Opiant Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 22nd.
Opiant Pharmaceuticals (OPNT) opened at $21.50 on Friday. The stock has a market capitalization of $44.46, a P/E ratio of 51.19 and a beta of -0.28. Opiant Pharmaceuticals has a 12-month low of $5.00 and a 12-month high of $51.90.
Opiant Pharmaceuticals (NASDAQ:OPNT) last released its quarterly earnings results on Monday, December 4th. The technology company reported ($2.77) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by ($1.58). Opiant Pharmaceuticals had a return on equity of 42.44% and a net margin of 8.93%. The company had revenue of $0.02 million during the quarter.
In other news, major shareholder Geoffrey Wolf sold 2,570 shares of the company’s stock in a transaction on Friday, December 8th. The stock was sold at an average price of $30.40, for a total transaction of $78,128.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 63.82% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Q2 2018 EPS Estimates for Opiant Pharmaceuticals Inc (NASDAQ:OPNT) Raised by Analyst” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/01/14/zacks-investment-research-brokers-raise-earnings-estimates-for-opiant-pharmaceuticals-inc-opnt.html.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).
Get a free copy of the Zacks research report on Opiant Pharmaceuticals (OPNT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.